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Contrast-enhanced ultrasound (CEUS) has recently become one of the most versatile and powerful diagnostic tools in vascular
surgery. One of the most interesting fields of application of this technique is the study of the carotid atherosclerotic plaque
vascularization and its correlation with neurological symptoms (transient ischemic attack, minor stroke, and major stroke) and
with the characteristics of the “vulnerable plaque” (surface ulceration, hypoechoic plaques, intraplaque hemorrhage, thinner fibrous
cap, and carotid plaque neovascularization at histopathological analysis of the sample after surgical removal). The purpose of this
review is to collect all the original studies available in literature (24 studies with 1356 patients enrolled) and to discuss the state of
the art, limits, and future perspectives of CEUS analysis.The results of this work confirm the reliability of this imaging study for the
detection of plaques with high risk of embolization; however, a shared, user-friendly protocol of imaging analysis is not available
yet. The definition of this operative protocol becomes mandatory in order to compare results from different centers and to validate
a cerebrovascular risk stratification of the carotid atherosclerotic lesions evaluated with CEUS.
1. Introduction
CEUS represents one of the major breakthroughs in the
field of diagnostic ultrasound. In fact, the contrast medium,
injected intravenously, passes through the vascular region of
interest generating an enhanced ultrasound signal that allows
a better morphological and functional imaging resolution [1].
Moreover the simplicity and rapidity of execution even at
the patient’s bedside encouraged its application for different
vascular purposes: the definition of the degree of stenosis
and plaque surface (i.e., higher sensitivity for plaque ulcer-
ation or near-occlusion stenosis), the diagnosis of intrastent
restenosis, the detection of type II endoleaks (even those with
low flow rate), the assessment of organ perfusion (i.e., kid-
ney transplantation), or the assessment of tumor perfusion
(important prognostic parameter in metastatic tumors) [2].
Another interesting field of application of CEUS is the study
of the carotid atherosclerotic plaque vascularization and its
correlation with cerebrovascular neurological events (stroke,
transient ischemic attack). Data available from large study
population in literature reveal a 5-year risk for ipsilateral
stroke of 5% of patients with asymptomatic carotid artery
stenosis of 70% or greater [3–5]. The traditional parameters
for the description of a carotid atherosclerotic plaque (degree
of stenosis, systolic peak velocity) are insufficient predictors
of the risk of embolization while the vascularization of the
atherosclerotic plaque, evaluated with CEUS, is correlated
with a more accurate “qualitative” analysis of the carotid
disease [2]. Differently from what happens for the other
fields of application of CEUS, the study of the carotid plaque
vascularization requires a more precise quantification of the
enhancement which is obtained by a visual or semiautomated
method [6]. The objective of this review is to analyze the
application of CEUS for the study of plaque microvascular-
ization in carotid atherosclerosis and to define the strengths
and limits of this technique.
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Figure 1: (a) Histopathological preparation of a carotid atherosclerotic plaque colored with CD31 endothelial-specific stain (brown)
showing the close correlation between plaque vascularization and the inflammatory response. (b) Histopathological preparation of a carotid
atherosclerotic plaque colored with CD31 endothelial-specific stain (brown) showing larger microvessels (red arrows) and areas of plaque
hemorrhage.
2. Correlation between Plaque
Microvascularization and Potentially
Symptomatic Atherosclerotic Lesions
The inflammatory etiopathogenesis of atherosclerosis has
been widely demonstrated in several animal models and later
confirmed in human models [7]. In particular at the level
of flow turbulence along the vascular tree (vessel bifurca-
tion), the subintimal deposition of cholesterol and oxidized
lipoproteins generates an inflammatory response with the
recruitment of white blood cells, primarily macrophages, and
the production of cytokines and enzymes. Among different
cellular responses to the inflammatory stimulus there is the
liberation from the smoothmuscles cells of vascular endothe-
lial growth factor (VEGF) with the consequent activation
of neoangiogenesis of the vessel wall (Figure 1). The newly
formed vessels inside the atherosclerotic plaque however
are immature and leaky due to reduced gap junctions,
thus serving as a port of entry for other inflammatory
cells, lipids, and even red blood cells, which contribute to
plaque growth. In the same contest macrophages produce
metalloproteinases, like MMP-9 and other collagenases that
destroy the connective fibrous tissue, thus stimulating the
neovessels growth [8]. All these plaque changes lead to a vul-
nerable atherosclerotic plaque [7]. It is common experience in
clinical practice that irregular, ulcerated plaque surfaces, lipid
necrotic core, thin fibrous cap, anechoic-hypoechoic appear-
ance, and intraplaque neovessels characterize potentially
unstable atherosclerotic lesions with high risk of emboliza-
tion and thrombosis. However, it is common experience that
not all the atherosclerotic lesions behave in the same way.
In fact some of them react to the inflammation stimulus
with the precipitation of calcium salts (calcific plaques) and
others with the simple transformation of muscular cells into
connective cells (fibrous plaques). The exact mechanism of
differentiation of the plaque is still partially unknown but
some factors, such as genetic predisposition, uncontrolled
risk factors like smoke, diabetes mellitus, hypertension, and
dyslipidemia, may influence the process.
3. Methods
3.1. Search Strategy. This review included all available original
studies reporting the use of CEUS for the evaluation of
the vascularization of the carotid atherosclerotic plaque and
its correlation with ipsilateral neurological events and with
other indicators of plaque “vulnerability”. Data were collected
from the online MEDLINE database in July 2014 using
PubMed (National Center for Biotechnology Information,
US National Library of Medicine, Bethesda, MD).The search
strategy included the words “carotid,” “atherosclerosis,” and
“contrast-enhanced.” No time restriction for publication date
was used. The search was restricted to articles published in
English and to studies in humans.
3.2. Study Selection, Data Extraction, and Analysis. All
abstracts were reviewed online and articles meeting the
inclusion criteria were identified and downloaded for data
extraction. In addition, a manual search of the reference lists
of the identified studies was performed, and references were
evaluated. Data collected from the selected studies were reg-
istered into a specific database and analyzed with Microsoft
Excel 2010 (Microsoft Corporation, Redmond, WA). Despite
the heterogeneity of the studies it was possible to create
different macrocategories of correlation between the degree
of the enhancement of the atherosclerotic lesion and neuro-
logical symptoms (transient ischemic attack, minor stroke,
and major stroke) or other plaque characteristics: histology
(quantification of the microvascularization of the carotid
plaque after surgical removal), echogenicity with Doppler
ultrasound (evaluated with a visual assessment according
to the Gray Weale scale—GW scale—or with a software
analysis according to the Gray Scale Median—GSM), signs
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of microembolization, or plaque instability (plaque surface
ulceration, cerebral ipsilateral microembolization detected
with transcranial Doppler ultrasonography in absence of
other possible causes).
4. Results
The search identified 24 original studies (100% single-center
studies) suitable for revision from 2007 to 2014 (Table 1) [9–
32]. The review population consisted of 1356 patients with
carotid atherosclerosis examined with CEUS; 946 patients
(70%) were asymptomatic. In 19 studies (76%) the con-
trast medium used was SonoVue (Bracco, Altana Pharma,
Konstanz, Germany), 2 studies (7%) used Definity (Bristol-
Myers Squibb Medical Imaging, Billerica, Massachusetts),
and 3 studies (7%) used Optison (GE Healthcare, Little Chal-
font, Buckinghamshire, UK). CEUS imaging of the carotid
artery was performed using linear array vascular probe with
transmission frequencies ranging from 3 to 15MHz and
mechanical index ranging from 0.06 to 1.4.The analysis of the
contrast enhancement was performed with a semiautomated
software in 16 studies (often home-made software). In 15
studies, a visual classification of the plaque enhancement
was performed by two different operators (nonuniformity in
scoring methods). In 7 studies (29%) plaques were evaluated
with both methods. The correlation between data obtained
with CEUS and histopathologic results was performed in 12
studies (50%, 433 patients) and all the studies found a statisti-
cal significant correlation: plaques with higher enhancement
have a highly significant vascularization of the plaque. Ten
studies (41%, 578 patients) evaluated the correlation between
CEUS images and the presence of ipsilateral neurological
symptoms: in three cases (30%, 91 patients) results did not
reach statistical significance to demonstrate that plaques with
greater contrast enhancement are more frequently related to
clinical symptoms. In 7 studies (29%, 331 patients) CEUS
analysis was compared to the plaque echogenicity; all the
studies found a statistically significant correlation: plaques
with high contrast enhancement have a low echogenicity.
Six studies (25%, 351 patients) compared CEUS with other
indicators of “vulnerable plaque” (surface ulceration, cerebral
microembolization detected with transcranial Doppler); all
the studies found a statistically significant correlation: the
increased vascularization of carotid atherosclerotic plaques
evaluated with CEUS is more frequently related to cerebral
microembolization or surface ulceration. One study (4%,
143 patients) compared CEUS to the patient’s gender with a
statistically significant correlation (𝑃 = 0.03): women have a
higher contrast enhancement of the carotid plaque.
5. Discussion
5.1. Correlation between CEUS and the Characteristics of the
Vulnerable Carotid Plaque. Data collected from an overall
review population of 1356 patients demonstrate that informa-
tion obtained by CEUS imaging is strictly dependent not only
on the plaque microvascularization (histological analysis)
but also correlated to the plaque echogenicity, the surface
ulceration, and the intraplaque hemorrhage (100% agreement
among the studies). All these parameters together define
an atherosclerotic plaque with high risk of embolization. In
detail plaques with low echogenicity, surface ulceration, and
histopathological findings of intraplaque hemorrhage have
a greater enhancement with CEUS compared to calcific or
fibrous plaques. Results on the correlation between CEUS
and clinical neurological symptoms do not reach statistical
evidence in all the studies; in fact 7 studies (487 patients)
established a significant relationship between the two param-
eters while 3 studies (91 patients) did not reach statistical
significance.The reason of this finding is not completely clear:
according to the general agreement among the studies on
the reliability of CEUS for the detection of a “vulnerable
plaque,” it would be logical to expect also a correlation with
neurological symptoms. However these results could be par-
tially explained with the low single-center study population
or with silent neurological damage among asymptomatic
patients. From the results obtained, CEUS appears to be
one of the most reliable imaging studies for the detection of
atherosclerotic lesions with high risk of embolization because
of the correlation with every single expression of the plaque
instability (intraplaque hemorrhage, surface ulceration, low
echogenicity, and plaque microvascularization). In current
literature there is not a specific indication for the “suitable
patient” for CEUS analysis; however, the strong relationship
between the plaque enhancement and the echogenicity of
the carotid plaque led some authors to select a subgroup of
the population (asymptomatic with an hypoechoic carotid
plaque) that would benefit most from this investigation [19].
5.2. CEUS Imaging Analysis. The acquisition of CEUS images
was made with different ultrasound hardware and differ-
ent presettings (i.e., mechanical index, linear probes). The
majority of the studies used a linear probe with frequencies
between 3MHz and 10MHz. The mechanical index as well
differs among the studies; however, many authors agree that
a lower mechanical index (between 0.06 and 0.2) is preferred
to obtain a better image resolution and to reduce the risk of
rupture of the microbubbles of contrast agent [33].
The analysis of the images obtained with CEUS can be
performed in two ways: the semiautomated method and the
visual score of the enhancement; often they are used together.
The semiautomated assessment is performed with a software
(usually a home-made software) that analyzes the variation
of enhancement intensity over time in a region of interest
(ROI). The timing of the analysis differs among the studies
(i.e., evaluation of maximum signal intensity [19], evaluation
of the late phase of contrast enhancement [23]) as well as
the unit of measurements (i.e., dB-enhanced [20], percentage
ratio between area of plaque captation and silent areas [19]).
Strengths of this method are a better reproducibility over
time with the same software and presetting and the reduction
of the operator-related bias. Some limits of this method are
the need of reprocessing the images (not immediate result)
and the need of a motion tracking algorithm (not simple
implementation) to reduce errors of interpretation on the
luminal side of the plaque. On the other hand, the visual
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score allows a direct interpretation of the CEUS examination
(easier applicability in a clinical setting) but with an increased
risk of operator-related bias and less accurate confrontation
of the results obtained. Moreover a univocal visual scale
is still not defined. Currently no data are available on the
superiority of the semiautomated analysis compared to the
visual assessment for CEUS. From the data collected in
literature it becomes mandatory to create a generally shared
operative protocol for the interpretation of CEUS results in
order to compare experiences from different centers.
5.3. Tolerability of CEUS. The contrast medium injected
intravenously consists of microbubbles filled with gasses (air
or high molecular weight gasses) and it has been shown
to have a good safety profile. In literature the three most
common side effects observed in clinical trials were headache
(2,3%), injection site pain (1,4%), and injection site bruising,
burning, or paresthesia (1,7%) [34]. Among the studies
evaluated in this review, 19 used SonoVue (Bracco), 3 used
Optison (GE Healthcare), and 2 studies performed CEUS
with Definity (Bristol-Myers). None of the studies reported
severe side effects, procedural complication, or anaphylactic
reactions to the contrast medium.
5.4. Limits and Future Perspectives of CEUS for the Study
of Carotid Atherosclerosis. Despite the excellent results
described above, some limits are still evident. Firstly CEUS
remains an operator dependent imaging technique; for this
reason the creation of a common semiautomated software for
the image elaboration could increase the reproducibility and
the homogeneity among different operators. Moreover the
sensibility of CEUS decreases in heavy calcified plaques with
important acoustic shadow. Lastly the bidimensional analysis
of the plaque enhancement assumes that the longitudinal
cross section of the plaque analyzed is representative of the
whole carotid plaque. For this reason it could be interesting
to apply the emerging technique of 3D and 4D Doppler
ultrasonography to CEUS for a global evaluation of the
carotid atherosclerotic lesion.
6. Conclusion
This review confirms the great potential of CEUS for the
detection of carotid atherosclerotic plaques with high risk
of embolization. However the different procedures used for
the analysis of the contrast enhancement limit the possibility
to compare results from different centers. The creation of a
common, well-established, user-friendly, and operative pro-
tocol is essential to overcome this limit to create multicentric
studies in order to define a cerebrovascular risk stratification
with accurate enhancement cut-offs.
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